A review of behavioural rating scales for the assessment of Attention 1 2 Deficit/Hyperactivity Disorder among adults in research. 3 Authorship Marius Grandjean^{1,2}, Shachar Hochman¹, Raja Mukherjee³, Roi Cohen Kadosh¹ 4 5 ¹School of Psychology, University of Surrey, Guildford GU2 7XH, United Kingdom 6 ²Psychological Sciences Research Institute, UCLouvain, Louvain-la-Neuve, Belgium 7 ³Adult Neurodevelopmental Service, Horizon House, Epsom, KT17 4QJ, United Kingdom 8 Correspondence: Dr Shachar Hochman (s.hochman@surrey.ac.uk) 9

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

10 Abstract

Objective: This review aims to provide researchers with a contemporary and comprehensive understanding of the current state of behavioural rating scales used in evaluating adult ADHD for research purposes. The objective is to offer guidance that enables researchers to make informed decisions when selecting the most suitable scale for their studies. Moreover, our intention was to map and compare these scales, with a specific focus on detecting feigned or invalid symptom presentation—an aspect notably overlooked in prior reviews.

Method: We reviewed the most recent literature on behavioural rating scales for adult ADHD
assessment. We evaluated the scales and compared them based on their psychometric
properties and the range of symptoms that they assessed.

20 Results: The Conners' Adult ADHD Rating Scales (CAARS), Mind Excessively Wandering Scale (MEWS), and Wender Utah Rating Scale (WURS) have emerged as the most accurate measures 21 for assessing adult ADHD. Moreover, there is an increasing emphasis on the development of 22 assessment tools, either integrated within existing scales or as independent measures, to 23 evaluate feigning or invalid symptom presentation. In that regard, stand-alone measures have 24 demonstrated greater effectiveness compared to embedded measures, with the ADHD 25 Symptom Infrequency Scale (ASIS) being identified as the most accurate scale for the detection 26 of feigning. 27

Conclusion: Based on this review, we provide recommendations for the behavioural rating
 scales with the most accurate measurement of relevant variables in research-related settings.

30 <u>Keywords</u>

31 Attention deficit hyperactivity disorder; behavioural rating scale; questionnaire;

32 psychometrics; adult; assessment.

34 Introduction

35 Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder exhibiting clinical heterogeneity, marked by the presence of a sustained tendency towards inattention 36 and distractibility, as well as hyperactivity and impulsivity, causing interference in functioning 37 or development (American Psychiatric Association, 2022). In many cases, ADHD continues to 38 affect individuals into adulthood, and can be associated with an increased risk of developing 39 other mental health disorders, as well as negative outcomes such as educational 40 underachievement, challenges with employment and interpersonal relationships, and 41 42 potential involvement with criminal activities (Sayal et al., 2018). The phenomenon of adult ADHD can be differentiated into two distinct subtypes, namely persistent and symptomatic 43 adult ADHD. The former subtype is characterised by the enduring presence of ADHD 44 symptoms over an extended period, spanning from childhood through adulthood. Conversely, 45 the latter subtype refers to the presence of clinically significant symptoms of ADHD that cause 46 impairment in daily functioning without a specific childhood-onset (Song et al., 2021). Recent 47 research has reported the global prevalence rates of persistent and symptomatic adult ADHD 48 to be 2.58% and 6.76% respectively, corresponding to 139.84 million and 366.33 million of 49 50 affected adults worldwide (Song et al., 2021).

51 When assessing adult ADHD, various methods are used, including interviews, continuous performance tests (CPTs), and behavioural rating scales. CPTs are computer-based 52 neuropsychological tests that require the individual to respond to a series of stimuli, 53 measuring specific cognitive functions that are impaired in ADHD. Meanwhile, behavioural 54 rating scales are subjective measures completed by either the individual or an informant. 55 These scales usually assess the frequency and severity of ADHD-related behaviours. While 56 57 clinical interviews have often been regarded as the gold standard for ADHD assessment 58 (Murphy & Gordon, 1998; Ramsay, 2015), a recent comprehensive review by Marshall et al. (2021) found that a combination of interviews, CPTs and behavioural rating scales result in the 59 highest rate of diagnostic accuracy. Unfortunately, such an extensive intervention may not 60 always be feasible (Kessler et al., 2005), and it is resource intensive. In research settings, 61 behavioural rating scales and/or CPTs are often used as the primary outcome of studies on 62 new treatment for ADHD (Allenby et al., 2018; Alyagon et al., 2020; Berger et al., 2021; 63 McGough et al., 2019; Nahum et al., 2023; Paz et al., 2018; Weaver et al., 2012). While several 64

65 studies have examined the effectiveness of CPTs (Baggio et al., 2020; Epstein et al., 2003; 66 Ogundele et al., 2011; Riccio & Reynolds, 2001; Vaughn et al., 2011), only a few have assessed the usefulness of behavioural rating scales (Harrison & Edwards, 2023; Marshall et al., 2021; 67 Taylor et al., 2011). Given their relatively low cost and quick administration, rating scales are 68 often favoured as the main outcome measure in studies focused on new treatments for ADHD 69 70 (Alyagon et al., 2020; McGough et al., 2019; Paz et al., 2018; Weaver et al., 2012). However, there is a relative lack of a clear understanding of the quality and adequacy of these rating 71 72 scales. This prevents researchers to make informed decisions when selecting which scale to 73 use and for what purpose.

To enhance the reader's understanding of the commonly used behavioural rating scales used 74 75 in the assessment of adult ADHD, we will provide a brief and non-exhaustive overview of the most frequently used measures for assessing adult ADHD. These rating scales are either 76 77 available publicly at no cost or commercially. Among the publicly available scales, there is the Wender Utah Rating Scale (WURS) which is a retrospective self-reported measure consisting 78 of 61 items that assess experienced childhood symptoms of ADHD in adults. A shorter version 79 of the WURS known as WURS-25 is also available (Ward et al., 1993). Another widely used 80 81 measure is the Adult ADHD Self-Report Scales (ASRS), which assesses the 18 symptoms of 82 ADHD outlined in the DSM-4 (Adler et al., 2006). In addition to the free measures previously mentioned, there are also commercially available measures. To begin, Barkley Adult ADHD 83 Rating Scale (BAARS-IV) has various subscales for assessing current and childhood symptoms 84 based on DSM-5 criteria. Each scale consists of 27 items and can be administered either 85 through self-report or by an observer (Barkley, 2011). Then, there is the Brown Attention-86 Deficit Disorder Scales (BADDS), which is a self-reported questionnaire consisting of 40 to 50 87 88 items divided into six subscales. It assesses symptoms associated with ADHD and executive 89 function impairments (Brown, 1996), as such impairments has been suggested to be one of the underlying mechanisms of ADHD (Barkley, 1997). Lastly, the Conners' Adult ADHD Rating 90 Scales (CAARS, long version) has 66 items that assess the presence and severity of ADHD 91 symptoms through statements about daily activities and behavioural tendencies. Similarly, to 92 the BAARS-IV, the CAARS also has both self- and observer-reported versions that comprise 93 identical items. 94

95 Interestingly, The CAARS also includes an Inconsistency Index, which is a measure for careless 96 or random responding (Conners et al., 1999). In addition to the original Inconsistency Index, researchers have developed two additional indexes for the CAARS aiming to support the 97 psychometric value of the CAARS; The first is the CAARS Infrequency Index (CII), which consists 98 of items from the CAARS that are rarely endorsed by individuals with or without ADHD. The 99 100 CII is useful for identifying overreporting of symptoms (J. A. Suhr et al., 2011). The second Index Is the Exaggeration Index (EI), which includes items from the Dissociative Experiences 101 102 Scale (DES) that are integrated into the CAARS. The EI measures the extent to which an 103 individual reports exaggerated or extreme symptoms of ADHD (Harrison & Armstrong, 2016).

In previous reviews, the CAARS was argumentatively recommended as the most useful 104 105 measure due to its psychometric properties (Taylor et al., 2011), its coverage of a large 106 constellation of symptoms and its ability to identify invalid symptom presentation (Marshall 107 et al., 2021), which is becoming an increasingly concerning issue. Over the last decade, studies have shown that behavioural rating scales can be easily falsified (Jachimowicz & Geiselman, 108 2004; Lee Booksh et al., 2010; Quinn, 2003). This issue is compounded by the fact that some 109 110 individuals may feign ADHD symptoms for a variety of reasons, such as to provide a socially 111 acceptable excuse for their difficulties (J. Suhr & Wei, 2013) or to obtain benefits associated with ADHD medication (Hinshaw & Scheffler, 2014). This is particularly concerning because 112 the non-specific and subjective nature of ADHD symptoms makes it easier for individuals to 113 feign symptoms during formal evaluations, which is especially prevalent among adults, 114 particularly college students. Additionally, the diagnostic criteria for adult ADHD, as 115 emphasised by the DSM-5, rely heavily on subjective symptoms rather than cognitive or 116 functional deficits. Therefore, when using behavioural rating scales to assess ADHD symptoms, 117 118 it is crucial to consider the possibility of feigned results. The primary objective of this paper is 119 to scrutinize the latest advancements concerning the utilisation of behavioural rating scales in the evaluation of ADHD symptoms. More specifically, this review aims to provide researchers 120 with an updated and comprehensive understanding of the current state of behavioural rating 121 scales utilized in the assessment of adult ADHD, to aid them in making informed decisions 122 when selecting an appropriate scale for their research (for a comprehensive analysis of the 123 124 diagnostic efficacy of behavioural rating scales for clinical utility, see Harrison & Edwards, 2023). 125

126 The traditional approach to compare rating scales used for ADHD assessment is by examining 127 their psychometric properties. However, there is no agreed-upon gold standard regarding which statistics are more important or how to determine when one scale is better than 128 another. In the present review, we chose to focus on evaluating the sensitivity, specificity, 129 PPV, and NPV of the rating scales. Consequently, before delving further into this review, we 130 131 briefly describe the fundamental statistics that we used. To begin, *sensitivity*, also referred to as the true positive rate, reflects the likelihood that a test or measurement accurately 132 133 identifies the presence of a specific condition. To elucidate, an ADHD rating scale with a 134 sensitivity of 0.60 would correctly identify ADHD in 60% of cases. Moving on, specificity, known as the true negative rate, signifies the probability of a test or measurement accurately 135 recognizing the absence of a particular condition. For instance, an ADHD rating scale boasting 136 a specificity of 0.30 would accurately identify the absence of ADHD in 30% of cases. 137 Transitioning to *positive predictive value* (PPV), which gauges the probability that an individual 138 possesses a condition if the test or measurement identifies them as having it. For example, an 139 ADHD rating scale with a PPV of 0.80 signifies that if the test indicates ADHD presence, there's 140 141 an 80% likelihood the individual indeed has ADHD. In contrast, negative predictive value (NPV) 142 assesses the probability that an individual lacks a given condition if the test or measurement 143 designates them as not having it. To provide an example, an ADHD rating scale with an NPV of 144 0.70 would imply a 70% probability of an individual not having ADHD if the test indicates so 145 (Ivnik et al., 2001).

In simpler terms, *sensitivity* measures how well a test can correctly find positive cases. On the 146 147 other hand, PPV looks at how likely it is that a positive test result truly means the person has the condition. This way, for example, it is possible to have a test that does not catch all positive 148 149 cases (low *sensitivity*), but when it does yield a positive result, it is usually correct (high PPV). 150 In contrast, *specificity* measures how well the test can correctly identify those without the condition (negative cases). The NPV, meanwhile, gauges how likely it is that a negative test 151 result truly means the person doesn't have the condition. Some authors argued that although 152 sensitivity and specificity are crucial in determining true positive and true negative, they fail 153 to account for the confidence level a test score can provide in either confirming or excluding 154 a diagnosis or condition. Likewise, PPV and NPV are useful in clinical decision-making because 155 they are influenced by the base rate (BR), which is the prevalence of the condition in the 156

157 population but do not indicate the frequency with which the test identifies the targeted 158 behaviour. Hence, it is strongly recommended to interpret all four values concurrently and use qualitative descriptors to interpret their clinical usefulness (Lange & Lippa, 2017) (see Table 159 1). 160

Table 1. Recommended qualitative descriptors for sensitivity, specificity, PPV and NPV 161 values as proposed by Lange & Lippa (2017). 162

Value as a percentage	Qualitative descriptor
<10	Very low
10-24	Low
25-39	Low-moderate
40-59	Moderate
60-74	Moderate-high
75-89	High
90-100	Very-high

163 *Note.* PPV = positive predictive value, NPV = negative predictive value.

Although behavioural rating scales should not be relied upon solely to clinically diagnose adult 164 165 ADHD (Harrison & Edwards, 2023), they are often regarded as a valuable tool in research 166 settings. This is particularly notable when the objective is to measure changes in symptoms 167 during the implementation of new treatments, prioritizing symptom assessment over establishing a conclusive diagnosis. This situation often prompts researchers to deliberate on 168 169 the most appropriate scale that aligns with their specific research objectives. This paper sets 170 out to elucidate the current status of these scales, offering in-depth insights into their 171 accuracy, the symptoms they effectively capture, and their distinct characteristics. Through 172 practical recommendations, this paper aims to empower researchers to make informed decisions when selecting the most suitable scale for their research endeavours. 173

Materials and Methods 174

We conducted a comprehensive search in the PubMed database between 2019 and February 175 2023, using the search terms "ADHD" AND "attention deficit hyperactivity disorder" AND 176 "assessment or testing or evaluation" AND "adult" AND "diagnosis" (see Figure 1). We 177 178 specifically chose these terms to match those used in the most recent review of adult ADHD assessment (Marshall et al., 2021) which examined the literature published between 1998 and 179 2019. Therefore, we selected 2019 as our starting point to provide an updated view of the 180

181 state of behavioural rating scales for adult ADHD assessment. Electronic publications were the 182 only publications considered for inclusion in the review. In the initial search, a total of 1264 abstracts of journal articles were identified, from which 73 were considered potentially 183 relevant to adult ADHD assessment. After a further consideration of the abstracts, the full 184 texts of 51 journal articles were reviewed, in addition to their bibliographies and citations, 185 which led to the identification and review of an additional 5 articles. The final phase of the 186 literature search aimed at identifying articles that met the inclusion criteria culminating in a 187 final sample of 11 articles (see Table 2). A detailed description of the reviewed papers can be 188 found in Appendix 1. 189

190 Figure 1. Flow diagram illustrating the literature search process and article selection.



191

192 Table 2. Inclusion criteria

-	Published in English peer reviewed	-	Neuropsychological	tests	are
	journals.		standardized and have	e normative	data.
-	ADHD is diagnosed by widely used	-	Results provide dia	gnostic acc	curacy
	clinical or research semi-structured or		statistics, at minimu	m sensitivity	y and
	structured interview.		specificity.		
-	Group study investigation behaviour	-	Participants are adult	s, 18 years	old or
	rating scales for diagnosis, screening, or		older.		
	identification of ADHD.				

Behavioural rating scales for the screening of ADHD 195

Two studies focused on distinguishing adults with ADHD from those without the condition, 196 while another two studies aimed to differentiate adults with ADHD from individuals diagnosed 197 198 with other psychiatric disorders.

199 The first study used the short version of the WURS (WURS-25) and the ASRS. They found that the WURS-25 had a high level of sensitivity 90% and specificity 88% and the ASRS scale 200 demonstrated a high level of sensitivity of 80% and specificity of 88% in distinguishing 201 between adults who were seeking assessment for ADHD and healthy controls. However there 202 203 were no mention of PPV nor NPV (Brevik et al., 2020). The second study compared the full version of the WURS with the WURS-25 and found that both versions had high sensitivity and 204 specificity values when distinguishing between control and ADHD groups. Specifically, the full 205 WURS had a sensitivity of 95%, a specificity of 93%, a PPV of 94%, and a NPV of 84%, while the 206 207 WURS-25 had a sensitivity of 91%, a specificity of 94%, a PPV of 88%, and an NPV of 91%. 208 When differentiating between ADHD and other psychiatric disorders, the full WURS had very high specificity of 94% and NPV of 91% and high sensitivity of 84% and PPV of 88%. In contrast, 209 the WURS-25 demonstrated high specificity of 85% and NPV of 79% and moderate-to-high 210 sensitivity of 62% and PPV of 73% (Gift et al., 2021). Then, Mowlem and colleagues (2019) 211 developed the Mind Excessively Wandering Scale (MEWS) to assess the presence of mind 212 wandering in individuals ADHD. The MEWS defines mind wandering as "periods in time in 213 214 which attention switches from a current task to unrelated thoughts and feelings" (Smallwood 215 & Schooler, 2015). The MEWS is a self-report measure consisting of 12 or 15 items, which are rated on a 4-point Likert-type scale ranging from 0 (indicating "not at all or rarely") to 3 216 (indicating "nearly all of the time or constantly"). In their study, the MEWS was found to have 217 a high level of sensitivity of 90% and specificity of 90% in the diagnosis of ADHD using sample 218 of patients with ADHD and healthy controls. The authors reported no PPV nor NPV (Mowlem 219 220 et al., 2019). Finally, a study was focused on the main scale of the CAARS and the t-scores, which are standardised scores that compares the individual score with the reference group. 221 222 They found that utilizing a t-score threshold of > 65 for the identification of ADHD was 223 associated with a moderate-to-high sensitivity of 64%, a high specificity of 86%, a moderate 224 PPV of 51%, and a moderate-to-high NPV of 71%. In contrast, employing a t-score threshold

of > 70 yielded a low sensitivity of 14%, a very-high specificity of 92%, a moderate PPV of 47%,
and a moderate-to-high NPV of 68% (Harrison et al., 2019).

227 The aforementioned studies presented varying outcomes in comparison to prior research conducted beyond the scope of the reviewed timeframe. For instance, Brevik et al., (2020) 228 229 found higher specificity (88%) for the ASRS than previously reported by other studies (ranging from 27% to 68%) (Dunlop et al., 2018; Pettersson et al., 2018; Söderström et al., 2014; van 230 de Glind et al., 2013). Similarly, Gift et al., (2021) found a higher specificity for the WURS (93-231 232 94%) compared to prior findings (ranging from 57% to 70%) (Luty et al., 2009; McCann et al., 233 2000). Finally, although the specificity of the CAARS generally remained high across studies, the sensitivity found by Harrison et al. (2019) (64%) was lower than previously reported (97%) 234 235 when the diagnosis is based on self and observer reports (Luty et al., 2009). These discrepancies between the studies may then be attributed to factors such as differences in 236 sample size, addition of informant's feedback, the proportion of ADHD subtypes, or whether 237 there was a clinical group. The latter is of particular issue because clinical settings typically 238 involve patients with other psychiatric conditions, such as depression and anxiety, that are 239 known to share comorbidities with ADHD (Anker et al., 2018; Kessler et al., 2006). As a result, 240 241 there is a higher risk of these patients being erroneously diagnosed.

242 Practical recommendations

243 Our findings yielded the following results, when differentiating between healthy controls and patients with ADHD, the WURS exhibited very-high sensitivity along with the WURS-25 and 244 the MEWS, whereas ASRS had high sensitivity, and the CAARS had moderate sensitivity. 245 Moreover, the WURS and the MEWS showed very-high specificity, while the WURS-25, ASRS 246 and CAARS demonstrated high specificity. The WURS also displayed very-high PPV with a high 247 NPV, whereas the CAARS exhibited moderate PPV with a moderate-to-high. Similarly, when 248 249 distinguishing between clinical patients and patients with ADHD, the WURS demonstrated very-high sensitivity, and the WURS-25 displayed moderate-to-high sensitivity. Both the WURS 250 and WURS-25 exhibited high specificity. The WURS had a high PPV and a very-high NPV, while 251 the WURS-25 displayed moderate-to-high PPV and high NPV. 252

Overall, research to date suggest that the CAARS, the MEWS and the WURS are the measureswith the best statistical properties for the assessment of adult ADHD (see appendix 2).

255 Behavioural Rating scales for the detection of feign ADHD symptoms

A total of seven studies explored indices designed to assess the validity of ADHD symptomsand the potential for feigning results.

To begin, two studies were focused on the validity indexes of the CAARS, which assess for the 258 detection of feigning and non-credible symptom presentation. Becke et al. (2021) created the 259 260 ADHD credibility index (ACI), a 12-items scale which was then compared with the CII. For the detection of feigning, the ACI had a very high specificity of 98%, a low-to-moderate sensitivity 261 of 30%, and PPV and NPV ranging from 69% to 95% and 58% to 92%, respectively, varying 262 263 between moderate and very high. Meanwhile, the CII had a very high specificity of 95%, a 264 moderate sensitivity of 46%, and PPV and NPV ranging from 51% to 90% and 63% to 94%, respectively, also varying between moderate and very high (Becke et al., 2021). The authors 265 also created the CII-ACI-Compound Index, a combination of items from both validity indexes. 266 The CII-ACI-Compound Index had a high specificity of 87% to 92%, a moderate sensitivity of 267 41% to 50%, and PPV ranging from 15% to 87% and NPV ranging from 60% to 97%, varying 268 between low-to-high and moderate-to-high and very high (Becke et al., 2022). Instead of 269 utilising embedded validity indices to detect feigning of ADHD symptoms, Courrégé and 270 271 colleagues (2019) developed a self-administered measure known as the ADHD Symptom 272 Infrequency Scale (ASIS). Comprising 52 true/false items, the ASIS is subdivided into two scales: the ADHD scale, which includes 19 items designed to align with DSM-5 diagnostic 273 criteria, and the Infrequency scale, which includes 33 items intended to be endorsed more 274 frequently by individuals simulating ADHD than those with a genuine diagnosis. Using a sample 275 composed of patients with diagnosed ADHD and instructed simulators, the infrequency scale 276 of the ASIS demonstrated a high sensitivity of 79% to 86%, specificity of 89%, PPV of 71% to 277 79%, and a very high NPV of 92% to 93% in the detection of feigning (Courrégé et al., 2019). 278 279 Another study, which included a clinical control group, reported that the infrequency scale of the ASIS had a very high specificity of 90%, moderate-to-high sensitivity of 71%, moderate-to-280 high PPV of 65%, and a very high NPV of 93% for detecting feigning (Skeel et al., 2022). Another 281 recent stand-alone measure, the Multidimensional ADHD Rating Scale (MARS), was developed 282 by Potts and colleagues (2021). The MARS includes three categories of items: 18 symptom 283 items, 22 impairment items, and 4 symptom-validity items. Additionally, three "catch" items 284 are incorporated into the assessment to measure effort and attention during the 285

286 administration. The items are rated on a scale ranging from 0 to 8, where the symptom scale ranges from 0 ("never") to 8 ("very often"), and the invalid scale ranges from 0 ("not at all") to 287 8 ("severe"). For the detection of ADHD, the MARS yielded a high sensitivity of 86% to 92%, a 288 moderate-to-high specificity of 58% to 67%, and PPV ranging from 60% to 65% and high NPV 289 of 86% to 92%. For the detection of feigning, the infrequency scale of the MARS showed a very 290 291 high specificity of 92%, a moderate-to-high sensitivity of 65%, very high PPV of 92%, and moderate-to-high NPV of 65% (Potts et al., 2021). In another study using a similar sample, the 292 293 infrequency scale of the MARS and found a specificity of 88%, a moderate-to-high sensitivity 294 of 62%, and moderate-to-high PPV of 63-88% and NPV of 69-87% for the detection of feigning (Potts et al., 2022). Finally, a recent study by Harrison et al. (2022) examined the validity of 295 two new indicators proposed by Aita et al. (2018) for identifying feigned ADHD using the 296 Personality Assessment Inventory (PAI). The PAI is a self-report personality measure consisting 297 of 344 items divided into four scales in which respondents are required to rate each item on 298 a four-point Likert scale ranging from 1 (indicating "false") to 4 (indicating "very true") (Morey, 299 1991). The study utilized a sample of patients with genuine ADHD and healthy controls who 300 301 were asked to either respond truthfully or feign ADHD. The results revealed that the Item-FAA 302 (Feigned Adult ADHD index using PAI items) had a high specificity of 78%, a moderate 303 sensitivity of 45%, a low PPV of 19%, and a very high NPV of 92%, while the Scale-FAA (Feigned 304 Adult ADHD index using PAI Scales) had a high specificity of 79%, a low-to-moderate sensitivity 305 of 36%, a low PPV of 17%, and a very high NPV of 91% for the detection of feigning (Harrison 306 et al., 2022).

307 It is noteworthy that the CAARS stands out among behavioural rating scales in that it possesses 308 validity indicators capable of detecting feigned symptoms. In addition to its initial infrequency index, the CII (J. A. Suhr et al., 2011) and the EI (Harrison & Armstrong, 2016), a new index, 309 310 the ACI, was recently developed (Becke et al., 2021). Although the ACI had very-high sensitivity, its specificity was found to be low-to-moderate. To improve its overall classification 311 accuracy, the authors of the study developed the CII-ACI-Compound, which showed a very 312 high sensitivity but only a moderate specificity (Becke et al., 2022). Although these indexes 313 show promise, further research is necessary to improve their accuracy. Additionally, they are 314 based on different theoretical foundations and may identify various subgroups of examinees 315 316 as non-credible (Becke et al., 2021). Conversely, as opposed to measures embedded within

existing rating scales, some authors have created stand-alone measures that assess ADHD directly while accounting for the existence of feigned symptoms. In spite of the fact that the MARS has shown promise in previous studies (Potts et al., 2021, 2022), its efficacy has not yet been tested on clinical groups, which may have led to inflated results, as explained earlier. On the contrary, the ASIS has exhibited good psychometric properties in its initial validation study (Courrégé et al., 2019) and these findings have already been replicated with a sample of patients reporting symptoms of depression and anxiety (Skeel et al., 2022).

324 Practical recommendations

325 In recent years, there has been a growing emphasis on developing assessment tools aimed at 326 detecting feigned symptoms. This focus arises from the recognition of the inherent 327 subjectivity and lack of specificity in the symptoms evaluated by behavioural rating scales. Current research indicates that stand-alone measures like the ASIS and the MARS exhibit 328 greater accuracy compared to embedded measures. Although these stand-alone measures 329 hold considerable promise, it's crucial to acknowledge that they are still in the process of 330 refinement and development. Given this evolving landscape, we suggest utilizing the CAARS 331 in conjunction with either the CII or the EI. This recommendation is made with the 332 333 understanding that further research is necessary to optimize these emerging indices and 334 augment their efficacy.

335 Discussion

336 <u>Recommendations for research settings</u>

337 The examination of the existing literature on the use of behavioural rating scales for adult 338 ADHD assessment revealed that they come in various forms and can evaluate different ranges of symptoms (see Figure 2). For example, the WURS primarily assesses childhood symptoms, 339 whereas the CAARS assesses current symptoms and can be used to monitor symptom changes 340 over time. Therefore, we emphasize that the selection of a behavioural rating scale should be 341 342 based on the primary variable of interest or research objectives. Nonetheless, for a measure that is suitable across a wide range of contexts, we endorse the findings of previous reviews 343 (Marshall et al., 2021; Taylor et al., 2011) and strongly recommend the utilisation of the 344 CAARS. It should be completed collaboratively by both the patient and a pertinent informant, 345 along with either the CII or the EI. 346

We propose this scale for the following compelling reasons. Firstly, the literature has identified 347 348 the CAARS as one of the most accurate measures available. Secondly, the CAARS is a 349 comprehensive tool that assesses a broad range of ADHD symptoms beyond those outlined in the DSM-5 as opposed to the WURS or the ASRS. Thirdly, the CAARS is strengthened as a 350 standalone instrument by its inclusion of validity indicators, which not only enhance its overall 351 utility but also assist in identifying cases where symptoms may have been inaccurately 352 presented. Finally, as previously mentioned, the CAARS is particularly advantageous for 353 studies assessing the efficacy of new ADHD treatments due to its ability to evaluate the current 354 presence and severity of ADHD symptoms. Unlike the WURS, which focuses on historical 355 symptoms, the CAARS can monitor changes in symptoms over time, allowing for a 356 comprehensive assessment of treatment effectiveness. Although the ASIS and MARS are more 357 effective at detecting invalid symptom presentation as well as feigning, they are still 358 359 underdevelopment and requires independent validation of their effectiveness by other researchers. Accordingly, the validity indicators of the CAARS remain the most optimal choice 360 thus far. 361

Figure 2. Tree-graph representing behavioural rating scales used in the assessment of adult ADHD.



364

Note. The measures are highlighted in green if they are publicly available, in red if they are commercially available and in blue if they are still under development. Note that the CII and EI are in red because they rely on the utilisation of the CAARS. The validation mark emphasizes the rating scales that we recommend based on their accuracy. Narrowband measures refer to scales that focus solely on evaluating specific symptoms associated with ADHD. Broadband measures are assessing a wider range of behaviours. WURS = Wender Utah Rating Scale. ASRS = ADHD self-report scale. CAARS =

371 Conner's Adult ADHD Rating Scales. CII = CAARS Infrequency Index. ACI = ADHD Credibility Index. ASIS = ADHD Symptom Infrequency Scale. BAARS-IV = Barkley Adult ADHD Rating Scale-Fourth Edition. El = 372 373 Exaggeration Index. MEWS = Mind Excessively Wandering Scale. MARS = Multidimensional ADHD 374 Rating Scale.

375 Strength and limitations

When interpreting the findings of this review, it is important to consider both its strengths and 376 limitations. One potential limitation is that only the Medline database was searched, and the 377 search only retrieved electronic articles. As a result, there's a possibility of publication bias 378 379 due to the lack of other sources of information. Another constraint of this paper lies in the instability observed in the base rates of PPV and NPV among the studies reviewed. The 380 variations in these base rates made it challenging to establish a meaningful direct comparison 381 between them and might have led to overestimation of their accuracy. While this paper aimed 382 to update and expand the results of Marshall et al. (2021), we decided not to control for the 383 presence of a clinical group. Therefore, some of the experiments reviewed may not accurately 384 reflect the use of rating scales in a clinical environment, where patients may present other 385 clinical diagnoses that are comorbid with ADHD. Moreover, our decision to apply inclusion 386 387 criteria that were more flexible than those of Marshall et al. (2021) is a distinct strength of our approach. This choice not only enabled a comprehensive review of a greater number of 388 papers, but also aligned with the research-oriented nature of our focus. Certainly, we 389 390 recognize that researchers frequently give precedence to evaluating symptoms rather than exclusively concentrating on achieving a diagnosis, as typically seen in clinical contexts. 391 392 Another strength is our focus on scales detecting feigned or invalid symptom presentation which were often overlooked in prior reviews. 393

394 Conclusion

The objective of this paper was to provide updated insights for researchers by examining 395 recent developments in the use of behavioural rating scales to assess adult ADHD for research 396 397 purposes. The growing body of research on these scales has raised concerns about their 398 susceptibility to feigning, highlighting the need to consider the objectives of the ADHD assessment when choosing rating scales. While standalone measures may be more 399 appropriate for research settings, combining different measures can enhance diagnostic 400 accuracy in clinical settings. To enhance the practical applicability of feigning measures, 401 further research should involve clinical groups to validate their effectiveness in settings that 402

- 403 closely reflects the clinical reality. Future studies should also systematically report sensitivity
- 404 and specificity along with PPV and NPV to make to facilitate their comparison with existing
- 405 measures.
- 406 Funding details.
- 407 The work was supported by the MRC Impact Acceleration Grant to Roi Cohen Kadosh.
- 408 Disclosure statement.
- 409 R. Mukherjee has delivered presentations for several pharmaceutical companies specializing
- in ADHD, whereby the funds generated were specifically allocated to the neurodevelopmental
- 411 teams, with no direct financial compensation received by the author. The remaining authors
- 412 declare no conflicts of interest.

414 <u>References</u>

415	Adler, L. A., Spencer, T., Faraone, S. V., Kessler, R. C., Howes, M. J., Biederman, J., & Secnik, K. (2006).
416	Validity of Pilot Adult ADHD Self- Report Scale (ASRS) to Rate Adult ADHD Symptoms. Annals
417	of Clinical Psychiatry, 18(3), 145-148. https://doi.org/10.3109/10401230600801077
418	Allenby, C., Falcone, M., Bernardo, L., Wileyto, E. P., Rostain, A., Ramsay, J. R., Lerman, C., &
419	Loughead, J. (2018). Transcranial direct current brain stimulation decreases impulsivity in
420	ADHD. Brain Stimulation, 11(5), 974-981. https://doi.org/10.1016/j.brs.2018.04.016
421	Alyagon, U., Shahar, H., Hadar, A., Barnea-Ygael, N., Lazarovits, A., Shalev, H., & Zangen, A. (2020).
422	Alleviation of ADHD symptoms by non-invasive right prefrontal stimulation is correlated with
423	EEG activity. NeuroImage : Clinical, 26, 102206. https://doi.org/10.1016/j.nicl.2020.102206
424	American Psychiatric Association. (2022). Diagnostic and Statistical Manual of Mental Disorders. DSM
425	Library. https://dsm.psychiatryonline.org/doi/book/10.1176/appi.books.9780890425787
426	Anker, E., Bendiksen, B., & Heir, T. (2018). Comorbid psychiatric disorders in a clinical sample of
427	adults with ADHD, and associations with education, work and social characteristics : A cross -
428	sectional study. <i>BMJ Open, 8</i> (3), e019700. https://doi.org/10.1136/bmjopen-2017-019700
429	Baggio, S., Hasler, R., Giacomini, V., El-Masri, H., Weibel, S., Perroud, N., & Deiber, MP. (2020). Does
430	the Continuous Performance Test Predict ADHD Symptoms Severity and ADHD Presentation
431	in Adults? Journal of Attention Disorders, 24(6), 840-848.
432	https://doi.org/10.1177/1087054718822060
433	Barkley, R. A. (1997). Behavioral inhibition, sustained attention, and executive functions :
434	Constructing a unifying theory of ADHD. <i>Psychological Bulletin</i> , 121(1), 65-94.
435	https://doi.org/10.1037/0033-2909.121.1.65
436	Barkley, R. A. (2011). Barkley Adult ADHD Rating Scale-IV (BAARS-IV) (p. x, 150). The Guilford Press.
437	Becke, M., Tucha, L., Weisbrod, M., Aschenbrenner, S., Tucha, O., & Fuermaier, A. B. M. (2021). Non-
438	credible symptom report in the clinical evaluation of adult ADHD : Development and initial
439	validation of a new validity index embedded in the Conners' adult ADHD rating scales.

440 Journal of Neural Transmission (Vienna, Austria: 1996), 128(7), 1045-1063.

441 https://doi.org/10.1007/s00702-021-02318-y

- 442 Becke, M., Tucha, L., Weisbrod, M., Aschenbrenner, S., Tucha, O., & Fuermaier, A. B. M. (2022). Joint
- 443 Consideration of Validity Indicators Embedded in Conners' Adult ADHD Rating Scales
- 444 (CAARS). *Psychological Injury and Law*, 15(2), 172-188. https://doi.org/10.1007/s12207-022-
- 445 09445-1
- 446 Berger, I., Dakwar-Kawar, O., Grossman, E., Nahum, M., & Cohen Kadosh, R. (2021). Scaffolding the

447 Attention-Deficit/Hyperactivity Disorder Brain Using Transcranial Direct Current and Random

448 Noise Stimulation : A Randomized Controlled Trial. *Clinical Neurophysiology*.

449 https://www.neuroscience.ox.ac.uk/publications/1152606

450 Brevik, E. J., Lundervold, A. J., Haavik, J., & Posserud, M.-B. (2020). Validity and accuracy of the Adult

451 Attention-Deficit/Hyperactivity Disorder (ADHD) Self-Report Scale (ASRS) and the Wender

452 Utah Rating Scale (WURS) symptom checklists in discriminating between adults with and

453 without ADHD. *Brain and Behavior*, *10*(6), e01605. https://doi.org/10.1002/brb3.1605

454 Brown, T. E. (1996). Brown attention-deficit disorder scales. TX: Psychological Corporation.

- 455 Conners, C. K., Erhardt, D., & Sparrow, M. A. (1999). Conner's Adult ADHD Rating Scales (CAARS).
- 456 New York : Multihealth Systems, Inc.
- 457 Courrégé, S. C., Skeel, R. L., Feder, A. H., & Boress, K. S. (2019). The ADHD Symptom Infrequency
- 458 Scale (ASIS) : A novel measure designed to detect adult ADHD simulators. *Psychological* 459 *Assessment*, 31, 851-860. https://doi.org/10.1037/pas0000706

460 Dunlop, B. W., Wu, R., & Helms, K. (2018). Performance of the Adult ADHD Self-Report Scale-v1.1 in

- 461 Adults with Major Depressive Disorder. *Behavioral Sciences (Basel, Switzerland)*, *8*(4), 37.
- 462 https://doi.org/10.3390/bs8040037
- 463 Epstein, J. N., Erkanli, A., Conners, C. K., Klaric, J., Costello, J. E., & Angold, A. (2003). Relations

464 Between Continuous Performance Test Performance Measures and ADHD Behaviors. *Journal*

465 of Abnormal Child Psychology, 31(5), 543-554. https://doi.org/10.1023/A:1025405216339

- 466 Gift, T. E., Reimherr, M. L., Marchant, B. K., Steans, T. A., & Reimherr, F. W. (2021). Wender Utah
- 467 Rating Scale : Psychometrics, clinical utility and implications regarding the elements of ADHD.
- 468 Journal of Psychiatric Research, 135, 181-188.
- 469 https://doi.org/10.1016/j.jpsychires.2021.01.013
- 470 Harrison, A. G., & Armstrong, I. T. (2016). Development of a symptom validity index to assist in
- 471 identifying ADHD symptom exaggeration or feigning. *The Clinical Neuropsychologist*, 30(2),
- 472 265-283. https://doi.org/10.1080/13854046.2016.1154188
- 473 Harrison, A. G., & Edwards, M. J. (2023). The Ability of Self-Report Methods to Accurately Diagnose
- 474 Attention Deficit Hyperactivity Disorder : A Systematic Review. Journal of Attention Disorders,
- 475 10870547231177470. https://doi.org/10.1177/10870547231177470
- 476 Harrison, A. G., Harrison, K. A., & Armstrong, I. T. (2022). Discriminating malingered attention Deficit
- 477 Hyperactivity Disorder from genuine symptom reporting using novel Personality Assessment
- 478 Inventory validity measures. *Applied Neuropsychology: Adult, 29*(1), 10-22.
- 479 https://doi.org/10.1080/23279095.2019.1702043
- 480 Harrison, A. G., Nay, S., & Armstrong, I. T. (2019). Diagnostic Accuracy of the Conners' Adult ADHD
- 481 Rating Scale in a Postsecondary Population. Journal of Attention Disorders, 23(14),
- 482 1829-1837. https://doi.org/10.1177/1087054715625299
- 483 Hinshaw, S. P., & Scheffler, R. M. (2014). *The ADHD explosion : Myths, medication, money, and*
- 484 *today's push for performance* (p. xxxii, 254). Oxford University Press.
- 485 Ivnik, R. J., Smith, G. E., Cerhan, J. H., Boeve, B. F., Tangalos, E. G., & Petersen, R. C. (2001).
- 486 Understanding the diagnostic capabilities of cognitive tests. *The Clinical Neuropsychologist*,
- 487 15(1), 114-124. https://doi.org/10.1076/clin.15.1.114.1904
- Jachimowicz, G., & Geiselman, R. E. (2004). *Comparison of Ease of Falsification of Attention Deficit* Hyperactivity Disorder Diagnosis Using Standard Behavioral Rating Scales.
- 490 Kessler, R. C., Adler, L., Ames, M., Demler, O., Faraone, S., Hiripi, E., Howes, M. J., Jin, R., Secnik, K.,
- 491 Spencer, T., Ustun, T. B., & Walters, E. E. (2005). The World Health Organization adult ADHD

492 self-report scale (ASRS) : A short screening scale for use in the general popula
--

- 493 *Psychological Medicine*, *35*(2), 245-256. https://doi.org/10.1017/S0033291704002892
- 494 Kessler, R. C., Adler, L., Barkley, R., Biederman, J., Conners, C. K., Demler, O., Faraone, S. V., Greenhill,
- 495 L. L., Howes, M. J., Secnik, K., Spencer, T., Ustun, T. B., Walters, E. E., & Zaslavsky, A. M.
- 496 (2006). The prevalence and correlates of adult ADHD in the United States : Results from the
- 497 National Comorbidity Survey Replication. *The American Journal of Psychiatry*, 163(4),
- 498 716-723. https://doi.org/10.1176/ajp.2006.163.4.716
- 499 Lange, R. T., & Lippa, S. M. (2017). Sensitivity and specificity should never be interpreted in isolation
- 500 without consideration of other clinical utility metrics. *The Clinical Neuropsychologist*, 31(6-7),
- 501 1015-1028. https://doi.org/10.1080/13854046.2017.1335438
- Lee Booksh, R., Pella, R. D., Singh, A. N., & Drew Gouvier, W. (2010). Ability of College Students to
- 503 Simulate ADHD on Objective Measures of Attention. *Journal of Attention Disorders*, 13(4),
- 504 325-338. https://doi.org/10.1177/1087054708329927
- Luty, J., Rajagopal Arokiadass, S. M., Sarkhel, A., Easow, J. M., Desai, R., Moorti, O. P., & El Hindy, N.
- 506 (2009). Validation of self-report instruments to assess attention deficit hyperactivity disorder
- 507 symptoms in adults attending community drug and alcohol services. *Journal of Addiction*

508 *Medicine*, *3*(3), 151-154. https://doi.org/10.1097/ADM.0b013e31819343d0

- 509 Marshall, P., Hoelzle, J., & Nikolas, M. (2021). Diagnosing Attention-Deficit/Hyperactivity Disorder
- 510 (ADHD) in young adults : A qualitative review of the utility of assessment measures and
- 511 recommendations for improving the diagnostic process. *The Clinical Neuropsychologist*,
- 512 35(1), 165-198. https://doi.org/10.1080/13854046.2019.1696409
- 513 McCann, B. S., Scheele, L., Ward, N., & Roy-Byrne, P. (2000). Discriminant Validity of the Wender
- 514 Utah Rating Scale for Attention-Deficit/Hyperactivity Disorder in Adults. *The Journal of*
- 515 *Neuropsychiatry and Clinical Neurosciences*, *12*(2), 240-245.
- 516 https://doi.org/10.1176/jnp.12.2.240

517	McGough, J. J.,	Sturm. A., Cow	en. J., Tung. K	Salgari. G. C.	. Leuchter. A. F.	. Cook. I. A., Su	gar. C. A., &
			•••••••••••••••••••••••••••••••••••••••	.,	,,		

- 518 Loo, S. K. (2019). Double-Blind, Sham-Controlled, Pilot Study of Trigeminal Nerve Stimulation
- 519 for Attention-Deficit/Hyperactivity Disorder. Journal of the American Academy of Child &
- 520 Adolescent Psychiatry, 58(4), 403-411.e3. https://doi.org/10.1016/j.jaac.2018.11.013
- 521 Mowlem, F. D., Skirrow, C., Reid, P., Maltezos, S., Nijjar, S. K., Merwood, A., Barker, E., Cooper, R.,
- 522 Kuntsi, J., & Asherson, P. (2019). Validation of the Mind Excessively Wandering Scale and the
- 523 Relationship of Mind Wandering to Impairment in Adult ADHD. Journal of Attention
- 524 Disorders, 23(6), 624-634. https://doi.org/10.1177/1087054716651927
- 525 Murphy, K. R., & Gordon, M. (1998). Assessment of adults with ADHD. In Attention-deficit
- 526 *hyperactivity disorder : A handbook for diagnosis and treatment, 2nd ed* (p. 345-369). The
- 527 Guilford Press.
- 528 Nahum, M., Dakwar-Kawar, O., Mairon, N., Hochman, S., Berger, I., & Cohen-Kadosh, R. (2023).
- 529 Transcranial Random Noise Stimulation combined with Cognitive Training for Treating ADHD :
- 530 A Randomized, Sham-Controlled Clinical Trial. https://doi.org/10.21203/rs.3.rs-2550466/v1
- 531 Ogundele, M. O., Ayyash, H. F., & Banerjee, S. (2011). Role of computerised continuous performance
- task tests in ADHD. *Progress in Neurology and Psychiatry*, 15(3), 8-13.
- 533 https://doi.org/10.1002/pnp.198
- Paz, Y., Friedwald, K., Levkovitz, Y., Zangen, A., Alyagon, U., Nitzan, U., Segev, A., Maoz, H., Koubi, M.,
- 535 & Bloch, Y. (2018). Randomised sham-controlled study of high-frequency bilateral deep
- 536 transcranial magnetic stimulation (dTMS) to treat adult attention hyperactive disorder
- 537 (ADHD) : Negative results. *The World Journal of Biological Psychiatry*, 19(7), 561-566.
- 538 https://doi.org/10.1080/15622975.2017.1282170
- 539 Pettersson, R., Söderström, S., & Nilsson, K. W. (2018). Diagnosing ADHD in Adults : An Examination
- 540 of the Discriminative Validity of Neuropsychological Tests and Diagnostic Assessment
- 541 Instruments. *Journal of Attention Disorders*, *22*(11), 1019-1031.
- 542 https://doi.org/10.1177/1087054715618788

- 543 Potts, H. E., Lewandowski, L. J., & Lovett, B. J. (2021). The Multidimensional ADHD Rating Scale : A
- 544 measure of symptoms, impairment, and symptom validity. *Journal of Clinical and*
- 545 *Experimental Neuropsychology*, 43(4), 426-436.
- 546 https://doi.org/10.1080/13803395.2021.1942795
- 547 Potts, H. E., Lewandowski, L. J., & Lovett, B. J. (2022). Identifying Feigned ADHD in College Students :
- 548 Comparing the Multidimensional ADHD Rating Scale to Established Validity Measures.
- 549 *Journal of Attention Disorders*, *26*(12), 1622-1630.
- 550 https://doi.org/10.1177/10870547221092095
- 551 Quinn, C. A. (2003). Detection of malingering in assessment of adult ADHD. Archives of Clinical

552 *Neuropsychology*, *18*(4), 379-395. https://doi.org/10.1093/arclin/18.4.379

- Ramsay, J. R. (2015). Psychological assessment of adults with ADHD. In *Attention-deficit hyperactivity disorder : A handbook for diagnosis and treatment, 4th ed* (p. 475-500). The Guilford Press.
- 555 Riccio, C. A., & Reynolds, C. R. (2001). Continuous Performance Tests Are Sensitive to ADHD in Adults
- 556 but Lack Specificity. Annals of the New York Academy of Sciences, 931(1), 113-139.
- 557 https://doi.org/10.1111/j.1749-6632.2001.tb05776.x
- 558 Sayal, K., Prasad, V., Daley, D., Ford, T., & Coghill, D. (2018). ADHD in children and young people :
- 559 Prevalence, care pathways, and service provision. *The Lancet Psychiatry*, *5*(2), 175-186.
- 560 https://doi.org/10.1016/S2215-0366(17)30167-0
- 561 Skeel, R. L., Lesica, S., Fust, B., Garnett, A., & Bolen, L. (2022). Validation of an adult ADHD measure of

feigning in a sample including individuals with depression and anxiety symptoms. *Applied*

- 563 *Neuropsychology: Adult, 0*(0), 1-7. https://doi.org/10.1080/23279095.2022.2158335
- 564 Smallwood, J., & Schooler, J. W. (2015). The Science of Mind Wandering : Empirically Navigating the
- 565 Stream of Consciousness. *Annual Review of Psychology*, 66(1), 487-518.
- 566 https://doi.org/10.1146/annurev-psych-010814-015331

- 567 Söderström, S., Pettersson, R., & Nilsson, K. W. (2014). Quantitative and subjective behavioural
- 568 aspects in the assessment of attention-deficit hyperactivity disorder (ADHD) in adults. *Nordic*
- 569 *Journal of Psychiatry*, *68*(1), 30-37. https://doi.org/10.3109/08039488.2012.762940
- 570 Song, P., Zha, M., Yang, Q., Zhang, Y., Li, X., & Rudan, I. (2021). The prevalence of adult attention-
- 571 deficit hyperactivity disorder : A global systematic review and meta-analysis. *Journal of*
- 572 *Global Health*, *11*, 04009. https://doi.org/10.7189/jogh.11.04009
- 573 Suhr, J. A., Buelow, M., & Riddle, T. (2011). Development of an infrequency index for the CAARS.
- 574 Journal of Psychoeducational Assessment, 29, 160-170.
- 575 https://doi.org/10.1177/0734282910380190
- 576 Suhr, J., & Wei, C. (2013). Symptoms as an Excuse : Attention Deficit/Hyperactivity Disorder Symptom
- 577 Reporting as an Excuse for Cognitive Test Performance in the Context of Evaluative Threat.
- 578 Journal of Social and Clinical Psychology, 32(7), 753-769.
- 579 https://doi.org/10.1521/jscp.2013.32.7.753
- 580 Taylor, A., Deb, S., & Unwin, G. (2011). Scales for the identification of adults with attention deficit
- 581 hyperactivity disorder (ADHD) : A systematic review. *Research in Developmental Disabilities*,
- 582 32(3), 924-938. https://doi.org/10.1016/j.ridd.2010.12.036
- van de Glind, G., van den Brink, W., Koeter, M. W. J., Carpentier, P.-J., van Emmerik-van
- 584 Oortmerssen, K., Kaye, S., Skutle, A., Bu, E.-T. H., Franck, J., Konstenius, M., Moggi, F., Dom,
- 585 G., Verspreet, S., Demetrovics, Z., Kapitány-Fövény, M., Fatséas, M., Auriacombe, M.,
- 586 Schillinger, A., Seitz, A., ... Levin, F. R. (2013). Validity of the Adult ADHD Self-Report Scale
- 587 (ASRS) as a screener for adult ADHD in treatment seeking substance use disorder patients.
- 588 Drug and Alcohol Dependence, 132(3), 587-596.
- 589 https://doi.org/10.1016/j.drugalcdep.2013.04.010
- 590 Vaughn, A. J., Epstein, J. N., Rausch, J., Altaye, M., Langberg, J., Newcorn, J. H., Hinshaw, S. P.,
- 591 Hechtman, L., Arnold, L. E., Swanson, J. M., & Wigal, T. (2011). Relation Between Outcomes

592	on a Continuous Performance Test and ADHD Symptoms Over Time. Journal of Abnormal
593	Child Psychology, 39(6), 853-864. https://doi.org/10.1007/s10802-011-9501-y
594	Ward, M. F., Wender, P. H., & Reimherr, F. W. (1993). The Wender Utah Rating Scale : An aid in the
595	retrospective diagnosis of childhood attention deficit hyperactivity disorder. The American
596	Journal of Psychiatry, 150(6), 885-890. https://doi.org/10.1176/ajp.150.6.885
597	Weaver, L., Rostain, A. L., Mace, W., Akhtar, U., Moss, E., & O'Reardon, J. P. (2012). Transcranial
598	Magnetic Stimulation (TMS) in the Treatment of Attention-Deficit/Hyperactivity Disorder in
599	Adolescents and Young Adults : A Pilot Study. <i>The Journal of ECT</i> , 28(2), 98.
600	https://doi.org/10.1097/YCT.0b013e31824532c8

601

603 <u>Note</u>

The MARS and the ASIS are still underdevelopment therefore not yet publicly nor commercially available. The WURS and ASRS are publicly available, the MEWS is available without charge by contacting <u>philip.asherson@kcl.ac.uk</u>. The ASRS, the CAARS and the WURS are commercially available.

609

610

Appendices

Appendix 1. Articles providing diagnostic accuracy for behaviour rating scale used in the 611

assessment of adult ADHD. 612

Reference	Participants	C-G	P/N	Measure	Relevant Outcome
Becke et	1001 credible	No	Yes	WURS-25,	The CAARS-ACI index was
al.,	neurotypical adult			ASRS, CAARS,	found to be useful in
2021	controls (median age 49),			CII, ACI,	distinguishing genuine
	22 overreporting			TOMM, GET.	patients with ADHD from
	neurotypical adult				simulators and symptom
	controls (median age 32),				over report but did not
	100 credible adults with				detect non-credible
	ADHD (median age 34),				adults diagnosed with
	22 non-credible adults				ADHD with adequate
	with ADHD (median age				accuracy.
	31,5)				
	242 adults instructed to				
	simulate (median age 20).				
Brevik et	646 adults with ADHD	No	No	WURS, ASRS.	Both the WURS and the
al.,	(mean age 34), 908 adult				ASRS exhibit high
2020	controls (mean age 29)				diagnostic accuracy, with
					the WURS showing
					superior discriminatory
					properties.
Courrégé et	Study 1: 30 adult	No	Yes	ASIS, BAARS-IV	The ASIS indicated strong
al.,	controls, 17 adults				internal consistency and
2019	thinking they have ADHD,				convergent validity with
	28 adults diagnosed with				the BAARS-IV. Moreover,
	ADHD, 31 adult				the ASIS was found to be
	simulators (group mean				nignly sensitive and
	age 33)				specific to maiingering.
	Study 2: 42 adult				
	thinking they have ADUD				
	thinking they have ADHD,				
	29 adults diagnosed with				
	ADHD, 31 adult				
	simulators (group mean				
	age 55).				
	controls 22 adults				
	thinking they have ADUD				
	26 adults diagnosed with				
	ADHD 38 adult				
	simulators (group mean				
	age 36).				
Gift et al.	137 adults with ADHD	Yes	Yes	WURS. WURS-	The full WURS was more
2021	(mean age 31), 230 adults			25	effective in distinguishing
	with major depression or				ADHD from MDD and

Reference	Participants	C-G	P/N	Measure	Relevant Outcome
	generalized anxiety disorder (MDD / GAD) (mean age 38), 120 adult controls (mean age 34)				GAD, compared to the WURS-25. On the other hand, the WURS-25 showed good separation of ADHD subjects from normal controls. However, the WURS performed better in differentiating ADHD patients from psychiatric controls, with higher sensitivity and specificity
Harrison et al., 2022	111 adults with ADHD (mean age 22), 66 clinical controls (mean age 23.8), 36 definite malingerers (mean age 23), 117 adults without diagnosis (mean age 23)	No	Yes	PAI, CII, EI, WMT, MSVT, TOMM, VSVT, TOVA.	The PAI algorithms proposed to identify feigned ADHD had low positive predictive value, hence they appear inadequate as symptom validity measures.
Mowlem et al., 2019	Study 1: 41 adults with ADHD (mean age 28), 47 adult controls (mean age 29). Study 2: 81 adults with ADHD (mean age 33), 30 adult controls (29)	No	No	MEWS, BRS, CAARS, ALS-SF, WFIRS- S	The MEWS has been found to be a dependable and credible tool to measure excessive mind wandering (MW) in adults diagnosed with ADHD. The study also revealed that individuals with ADHD reported substantially higher levels of MW when compared to their non-ADHD counterparts.
Skeel et al., 2022	101 adult controls, 99 adults with elevated DASS, 104 adults with diagnosed ADHD, 75 adult simulators (group mean age 42)	Yes	Yes	ASIS, BAARS- IV, DASS	The infrequency scale of the ASIS was deemed a trustworthy and effective measure for detecting ADHD feigning, even when individuals with symptoms of depression and anxiety were included in the sample.
Becke et al., 2022	856 adult controls (median age 50), 72 adults with ADHD (median age 35), 135 adult simulators (median age 39).	No	Yes	WURS-25, ASRS, CAARS, CII, ACI, TOMM, GET.	The combination of specific items from the CAARS Infrequency Index (CII) and the ADHD Credibility Index (ACI) in the CII-ACI-Compound index achieves a balance between sensitivity and specificity, but it does not

Reference	Participants	C-G	P/N	Measure	Relevant Outcome
					show significantly improved results compared to the use of the ACI alone.
Potts et al., 2021	Study 1: 39 adults with ADHD, 56 malingering adults, 62 adult controls (group mean age 19) Study 2: 49 adults with ADHD, 68 malingering adults, 70 adult controls (group mean age 18)	No	Yes	MARS	The MARS indexes could detect individuals with ADHD at high sensitivity rates but had moderate specificity with regard to non-ADHD controls. The infrequency index was effective in identifying genuine ADHD from malingered ADHD.
Potts et al., 2022	34 adults with ADHD (mean age 18), 34 malingering adults (mean age 18)	No	Yes	MARS, CAT-A, WMT	The infrequency scale of the MARS had a higher sensitivity rate of with close to optimal specificity compared to other tests for detecting feigned ADHD.
Harrison et al., 2019	507 clinical controls (mean age 22) and 249 adults with ADHD (mean age 21)	Yes	Yes	CAARS	The CAARS is reliable for screening (specificity) but not diagnosing (sensitivity). It often misidentified individuals has having ADHD when they presented other psychological conditions.

613 Note. C-G = Clinical Group. "Yes" was attributed if there was the presence of a clinical group. P/N = 614 predictive value. "Yes" was attributed if PPV & NVP were reported along with sensitivity and specificity. WURS = Wender Utah Rating Scale. WURS-25 = Wender Utah Rating Scale, Short-form. ASRS = ADHD 615 self-report scale. CAARS = Conner's Adult ADHD Rating Scales. CII = CAARS Infrequency Index. ACI = 616 ADHD Credibility Index. WMT = Word Memory Test. TOMM = Test of Memory Malingering, GET = 617 618 Groningen Effort Test. ASIS = ADHD Symptom Infrequency Scale. BAARS-IV = Barkley Adult ADHD Rating Scale-Fourth Edition. PAI = Personality Assessment Inventory. EI = Exaggeration Index. MSVT = Medical 619 620 Symptom Validity Test. VSVT = Victoria Symptom Validity Test. TOVA = Test of Variable of Attention. 621 MEWS = Mind Excessively Wandering Scale. BRS = Barkley ADHD Rating Scale. ALF-SF = Affective 622 Liability Scale-Short Form. WFIRS-S = Weiss Functional Impairment Rating Scale-Self Report. DASS = Depression Anxiety Stress Scales. MARS = Multidimensional ADHD Rating Scale. CAT-A = Clinical 623 624 Assessment of Attention Deficit-Adult.

625

626

627

629 Appendix 2. Psychometric statistics retrieved from the studies reviewed, arranged by measurement, and shorted by scale. 630

Measurement of ADHD								
Scale	Sensitivity %	Specificity %	PPV		Ν	IPV		
			Value %	BR %	Value %	BR %		
WURS-61	84-95	93-94	88-94		84-91			
WURS-25	62-90	85-94	73-88		79-91			
ASRS	80	88						
CAARS	64	86	51		71			
MARS	86-92	58-67	60-65	38-40	86-92	38-40		
MEWS	90	90	· ·			•		
Measurement of Fe	eigning	1						
Scale	Sensitivity %	Specificity %	PI	٧٧	Ν	IPV		
			Value %	BR %	Value %	BR %		
ACI	30	98	69-95	10-50	58-92	10-50		
CII	46	95	51-90	10-50	63-94	10-50		
ACI-CII	41	87	15-87	5-50	60-67	5-50		
ASIS	71-79	89-90	65-71	29	92-93	29		
MARS	62-65	88-92	63-92	25-50	69-87	25-50		
PAI Item-FAA	45	78	19	19	92	19		
PAI Scale-FAA	36	79	17	19	91	19		

631 Note. PPV = Positive predictive value. NPV = Negative predictive value. BR = base rate. WURS-61 = 632 Wender Utah Rating Scale, Long form. WURS-25 = Wender Utah Rating Scale, Short-form. ASRS = ADHD self-report scale. CAARS = Conner's Adult ADHD Rating Scales. MARS = Multidimensional ADHD Rating 633 Scale. MEWS = Mind Excessively Wandering Scale. ACI = ADHD Credibility Index. CII = CAARS 634 Infrequency Index. ACI-CII = ACI-CII Compound index. ASIS = ADHD Symptom Infrequency Scale. PAI: 635 636 Personality Assessment Inventory; Item-FAA: Feigned Adult ADHD index using PAI items; Scale-FAA: 637 Feigned Adult ADHD index using PAI Scales.